Bayer is pressing ... given alongside aspirin plus a P2Y12 inhibitor – at one year. Once again, there was no significant observed increase in bleeding with asundexian at any dose or compared ...

As low-dose prophylactic aspirin therapy becomes common among older people, potential risks that are associated with such treatment assume increasing importance. In particular, some clinicians are ...

Description The goal of the trial was to evaluate treatment with famotidine compared with placebo among patients taking low-dose aspirin. Hypothesis Famotidine would be more effective in ...

Recent guidelines have restricted aspirin use in the primary prevention of cardiovascular disease. The American Heart ...

Taking aspirin was first linked to a lower risk of colorectal cancer in 1988, but the research into its anti-tumour potential ...

Researchers from Florida Atlantic University argue that doctors should consider each patient's individual risk profile rather ...

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning ...

25). After a median follow-up of over two years, patients taking clopidogrel were 29% less likely than those taking aspirin to experience the trial's primary composite endpoint of all-cause death ...

Through rigorous assessment and prioritization, Bayer is advancing key programs with significant potential. (Image Credits: Pixabay) Bayer on Tuesday announced that it was preparing market ...

Bayer has claimed EU approval for Kerendia ... progression or renal death by 18% when added to the highest tolerated dose of standard therapy. The drug also cut cardiovascular outcomes ...